Hill May 24, 2024
The active ingredient in Ozempic and Wegovy may help reduce the risk of kidney failure in those with Type 2 diabetes and chronic kidney disease, according to a study published in the New England Journal of Medicine.
Researchers across 28 countries randomly assigned patients with Type 2 diabetes and chronic kidney disease to receive a weekly injection of 1 milligram of semaglutide, the active ingredient in Ozempic, or a placebo. Roughly 3,500 patients participated in the study, with half receiving semaglutide and the other half a placebo.
The study, which began in 2019, was funded by Novo Nordisk, which manufactures semaglutide.
In follow-ups among participants, the risk of a kidney disease events was found to be 24 percent lower in...
Today's Sponsors
Today's Sponsor